1.78
+0.05(+2.89%)
Currency In USD
Previous Close | 1.73 |
Open | 1.73 |
Day High | 1.78 |
Day Low | 1.69 |
52-Week High | 2.89 |
52-Week Low | 1.33 |
Volume | 145,246 |
Average Volume | 249,342 |
Market Cap | 52.63M |
PE | -0.84 |
EPS | -2.13 |
Moving Average 50 Days | 1.65 |
Moving Average 200 Days | 1.77 |
Change | 0.05 |
If you invested $1000 in Fortress Biotech, Inc. (FBIO) 10 years ago, it would be worth $40.23 as of May 24, 2025 at a share price of $1.78. Whereas If you bought $1000 worth of Fortress Biotech, Inc. (FBIO) shares 5 years ago, it would be worth $39.56 as of May 24, 2025 at a share price of $1.78.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference
GlobeNewswire Inc.
May 07, 2025 12:00 PM GMT
MIAMI, May 07, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equit
Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform
GlobeNewswire Inc.
Mar 17, 2025 12:55 PM GMT
FRANKFURT, Germany and MIAMI, March 17, 2025 (GLOBE NEWSWIRE) -- Partex NV and Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company, today announced a strategic collaboration aimed at identifying and evaluatin
Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT
GlobeNewswire Inc.
Jan 27, 2025 1:30 PM GMT
Study is the first randomized, controlled trial examining a vaccine’s effectiveness in controlling CMV in recipients of HSCT from vaccinated donors Encouraging pilot study results demonstrated the benefit of vaccinating donors with Triplex to convey